UroGen Pharma Ltd. Ordinary Shares (URGN)

Price$26.85

Value ScoreD

Growth ScoreA

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)-14.73%

Price vs S&P 500 (4W)-8.66%

VGM Score64.54

Market Capitalization$1.30B

All Metrics

Book Value / Share (Quarterly)$0.60

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)19.48%

Cash Flow / Share (Quarterly)$-3.41

Price vs S&P 500 (YTD)6.49%

Gross Margin (TTM)89.85%

Net Profit Margin (TTM)-94.83%

EPS (TTM)$-2.75

10-Day Avg Trading Volume0.61M

EPS Excl Extra (TTM)$-2.75

Revenue Growth (5Y)56.22%

EPS (Annual)$-3.19

ROI (Annual)-1319.29%

Gross Margin (Annual)88.66%

Net Profit Margin (5Y Avg)-161.00%

Cash / Share (Quarterly)$2.88

Revenue Growth QoQ (YoY)151.60%

ROA (Last FY)-76.57%

Revenue Growth TTM (YoY)52.92%

EBITD / Share (TTM)$-2.21

ROE (5Y Avg)-324.81%

Operating Margin (TTM)-77.02%

Cash Flow / Share (Annual)$-3.37

P/B Ratio50.79x

P/B Ratio (Quarterly)20.96x

Net Income / Employee (Annual)$-527,500

EV / Revenue (TTM)9.82x

Net Interest Coverage (TTM)-15.36x

ROA (TTM)-62.85%

EPS Incl Extra (Annual)$-3.19

Current Ratio (Annual)4.01x

Quick Ratio (Quarterly)3.89x

3-Month Avg Trading Volume0.81M

52-Week Price Return422.37%

Revenue / Employee (TTM)$482,800

Tangible BV / Share (Quarterly)$-1.36

P/S Ratio (Annual)11.80x

Asset Turnover (Annual)0.55x

52-Week High$32.37

Operating Margin (5Y Avg)-122.99%

EPS Excl Extra (Annual)$-3.19

CapEx CAGR (5Y)-25.03%

26-Week Price Return-6.80%

Quick Ratio (Annual)3.34x

13-Week Price Return36.92%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.69x

Enterprise Value$1.38B

Revenue / Share Growth (5Y)33.32%

Asset Turnover (TTM)0.66x

Revenue / Employee (Annual)$377,300

Inventory Turnover (Annual)0.97x

Pretax Margin (Annual)-139.74%

Cash / Share (Annual)$2.49

3-Month Return Std Dev63.64%

Gross Margin (5Y Avg)88.98%

Net Income / Employee (TTM)$-457,800

ROE (Last FY)-1319.29%

Net Interest Coverage (Annual)-11.84x

EPS Basic Excl Extra (Annual)$-3.19

Receivables Turnover (TTM)3.74x

Total Debt / Equity (Quarterly)4.77x

EPS Incl Extra (TTM)$-2.75

Receivables Turnover (Annual)4.11x

ROI (TTM)-41.46%

P/S Ratio (TTM)9.22x

Pretax Margin (5Y Avg)-158.27%

Revenue / Share (Annual)$2.28

Tangible BV / Share (Annual)$-3.86

Forward P/E511.79x

Price vs S&P 500 (52W)398.01%

Year-to-Date Return14.65%

5-Day Price Return-0.67%

EPS Normalized (Annual)$-3.19

ROA (5Y Avg)-70.37%

Net Profit Margin (Annual)-139.81%

Month-to-Date Return-4.55%

Cash Flow / Share (TTM)$-4.08

EBITD / Share (Annual)$-2.59

Operating Margin (Annual)-113.73%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-324.81%

LT Debt / Equity (Quarterly)4.77x

EPS Basic Excl Extra (TTM)$-2.75

P/B Ratio (Annual)25.38x

Inventory Turnover (TTM)1.00x

Pretax Margin (TTM)-98.45%

Book Value / Share (Annual)$0.37

Price vs S&P 500 (13W)28.67%

Beta1.61x

P/FCF (Annual)371.35x

Revenue / Share (TTM)$2.80

ROE (TTM)-204.47%

52-Week Low$4.80

vGradeD

gGradeA

mGradeA

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.47est. -0.49

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.21

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
URGNUroGen Pharma Ltd. Ordinary Shares	D	A	A	$26.85
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

UroGen Pharma is a biopharmaceutical company specializing in non-muscle invasive urothelial cancer treatments. The company commercializes two FDA-approved products—Jelmyto and Zusduri (both mitomycin-based)—which leverage its proprietary RTGel sustained-release technology to enhance therapeutic efficacy. Revenue is derived from United States sales of these approved oncology products.